patient death

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Class action lawsuit filed against $SLNO for allegedly concealing safety concerns and patient death related to experimental drug DCCR, causing significant shareholder losses.

Federal class action filed against $SLNO over alleged safety misrepresentations of DCCR drug. Stock fell 39% after safety revelations; investor deadline May 5, 2026.

Pomerantz LLP sues Soleno Therapeutics ($SLNO) over alleged securities fraud as stock plummets 39% following DCCR safety concerns and patient death disclosure. Lead Plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR safety concerns, patient death, and disappointing Q3 results that triggered sharp stock declines.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

Soleno Therapeutics ($SLNO) faces securities fraud lawsuit over DCCR drug for Prader-Willi syndrome. Stock plunged following safety concerns, patient death, and weak Q3 results.

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.